Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4461-4464

  Marfurt, Jutta ^a   Chalfein, Ferryanto ^b   Prayoga, Pak ^b   Wabiser, Frans ^b   Kenangalem, Enny ^b,c   Piera, Kim A ^a   MacHunter, Barbara ^a   Tjitra, Emiliana ^d   Anstey, Nicholas M ^a   Price, Ric N ^a,e  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c District Ministry of Health   (Indonesia)

^d NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMISININ; CHLOROQUINE; FERROQUINE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG UPTAKE; EX VIVO STUDY; HUMAN; HUMAN CELL; IC 50; MINIMUM INHIBITORY CONCENTRATION; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; SCHIZONT;

AMINOQUINOLINES; ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; FERROUS COMPOUNDS; PLASMODIUM FALCIPARUM;

EID: 80051807653     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01375-10     Document Type: Article

References (30)

1. Atteke, C., et al. 2003. In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J. Antimicrob. Chemother. 51:1021-1024. (Pubitemid 36503439)
2. Baird, J K 2007. Neglect of Plasmodium vivax malaria. Trends Parasitol. 23:533-539. (Pubitemid 350026468)
3. Baird, J K 2009. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev. 22:508-534.
4. Barends, M., A. Jaidee, N. Khaohirun, P. Singhasivanon, and F. Nosten. 2007. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar. J. 6:81.
5. Biot, C., et al. 2006. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem. 49:2845-2849.
6. Biot, C., G. Glorian, L A Maciejewski, and J S Brocard. 1997. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J. Med. Chem. 40:3715-3718. (Pubitemid 27481715)
7. Blackie, M A, et al. 2007. Metallocene-based antimalarials: An exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Bioorg. Med. Chem. 15:6510-6516. (Pubitemid 47302316)
8. Blackie, M A, and K. Chibale. 2008. Metallocene antimalarials: The continuing quest. Met. Based Drugs. 2008:495123.
9. Chim, P., et al. 2004. The in-vitro antimalarial activity of ferrochloroquine, measured against Cambodian isolates of Plasmodium falciparum. Ann. Trop. Med. Parasitol. 98:419-424. (Pubitemid 38903486)
10. Daher, W., et al. 2006. Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar. J. 5:11.
11. Delhaes, L., et al. 2001. In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites. Parasitol. Res. 87:239-244. (Pubitemid 32208941)
12. Delhaes, L., et al. 2002. Synthesis of ferroquine enantiomers: First investigation of Effects of metallocenic chirality upon antimalarial activity and cytotoxicity. Chembiochem 3:418-423. (Pubitemid 36002285)
13. Dive, D, and C. Biot. 2008. Ferrocene conjugates of chloroquine and other antimalarials: The development of ferroquine, a new antimalarial. ChemMedChem 3:383-391.
14. Douglas, N M, N M Anstey, B J Angus, F. Nosten, and R N Price. 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 10:405-416.
15. Genton, B., et al. 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: A prospective cohort study from Papua New Guinea. PLoS Med. 5:e127.
16. Henry, M., et al. 2008. In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 52:2755-2759.
17. Karyana, M., et al. 2008. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar. J. 7:148.
18. Kreidenweiss, A., P G Kremsner, K. Dietz, and B. Mordmuller. 2006. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 75:1178-1181. (Pubitemid 351627504)
19. Leimanis, M L, et al. 2010. Plasmodium vivax susceptibility to ferroquine. Antimicrob. Agents Chemother. 54:2228-2230.
20. Mendis, K., B J Sina, P. Marchesini, and R. Carter. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:97-106. (Pubitemid 32552576)
21. Pradines, B., et al. 2001. Ferrocene-chloroquine analogues as antimalarial agents: In vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J. Antimicrob. Chemother. 48:179-184. (Pubitemid 32755277)
22. Pradines, B., et al. 2002. In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop. Med. Int. Health 7:265-270. (Pubitemid 34264379)
23. Price, R N, N M Douglas, and N M Anstey. 2009. New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 22:430-435.
24. Price, R N, et al. 2007. Vivax malaria: Neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
25. Ratcliff, A., et al. 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: An open-label randomised comparison. Lancet 369:757-765. (Pubitemid 46335820)
26. Ratcliff, A., et al. 2007. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 101:351-359. (Pubitemid 46205894)
27. Richards, W H, and S G Williams. 1973. The removal of leucocytes from malaria infected blood. Ann. Trop. Med. Parasitol. 67:249-250.
28. Russell, B., et al. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045. (Pubitemid 351358386)
29. Suwanarusk, R., et al. 2007. Chloroquine resistant Plasmodium vivax: In vitro characterisation and association with molecular polymorphisms. PLoS One 2:e1089.
30. Tjitra, E., et al. 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua, Indonesia. PLoS Med. 5:e128.